THERAPY Neuroendocrine cancer-are two radionuclides better than one?

Dik Kwekkeboom

Research output: Contribution to journalArticleAcademicpeer-review

3 Citations (Scopus)

Abstract

Peptide-receptor radionuclide therapy with radiolabelled somatostatin analogues is a successful new treatment modality for patients with neuroendocrine tumours. Usually, (90)yttrium (Y-90)-coupled or (177)lutetium (Lu-177)-coupled somatostatin analogues are used, but a new study claims that combining the two radiopharmaceuticals results in improved overall survival.
Original languageUndefined/Unknown
Pages (from-to)326-328
Number of pages3
JournalNature Reviews Endocrinology
Volume8
Issue number6
DOIs
Publication statusPublished - 2012

Research programs

  • EMC MM-01-40-01

Cite this